Today: 2 July 2026
Palantir Stock Slides Before Earnings: Citi Cut Raises One Big Question
29 April 2026
2 mins read

Palantir Stock Slides Before Earnings: Citi Cut Raises One Big Question

New York, April 28, 2026, 18:06 EDT

Shares of Palantir Technologies slipped roughly 1.3% on Tuesday, dipping to around $141 after Citi lowered its price target on the stock to $210 from $260 but maintained its buy recommendation. The move adds extra weight just ahead of the data-analytics company’s upcoming earnings. Earlier in the day, the stock hit a session low near $140.42.

Timing’s key here. Palantir is scheduled to post its first-quarter numbers after the U.S. market shuts down on Monday, May 4. The webcast kicks off at 5 p.m. ET. Investors will be watching to see if appetite for its artificial-intelligence software can still justify one of the market’s loftier valuations.

Wall Street expects revenue to climb 74% on the year, with adjusted earnings per share coming in at 28 cents—figures that leave out certain costs, according to a Motley Fool piece run by Yahoo Finance. That same article points out Palantir shares have fallen nearly 20% so far this year, with the stock trading at a steep 226 price-to-earnings ratio. The company is also staring down possible competition in data analytics from both Snowflake and C3.ai.

Despite trimming his price target, Citi’s Tyler Radke kept an upbeat tone, citing sector-wide pressure on software valuations. “We expect continued momentum in Q1 in both U.S. government and commercial,” Radke wrote. He still sees Palantir as one of the “top artificial intelligence beneficiaries” as more enterprises adopt AI. Investors

In a separate piece for Seeking Alpha, Florian Muller took a more measured tone. According to Muller, Palantir’s risk-reward picture looks better after the stock’s 31% slide from its peak. Still, he argued, it’s going to take continued growth and margin expansion to justify the present valuation. As he put it, Palantir’s valuation has only shifted from “dark red” to “orange.” Seeking Alpha

Palantir set expectations sky-high with its latest report. Fourth-quarter 2025 revenue jumped 70% to $1.407 billion, according to the company, while U.S. commercial revenue soared 137%. Guidance now points to first-quarter revenue between $1.532 billion and $1.536 billion, and full-year 2026 revenue ranging from $7.182 billion to $7.198 billion. “We are an n of 1, and these numbers prove it,” CEO Alex Karp said at the time. Business Wire

Bulls circled fresh commercial headlines after Cleveland-Cliffs announced on Tuesday a three-year deal to roll out Palantir’s AI platform throughout its operations and commercial lines. CEO Lourenco Goncalves credited pilot results, calling Palantir the “platform of choice” for the steelmaker. Business Wire

But risk hasn’t disappeared. Germany’s military isn’t moving forward with Palantir contracts at this point, Reuters said Tuesday. Citing cyber defence chief Thomas Daum: “I don’t see that happening at all at the moment,” he told the outlet, pointing to current concerns about letting industry staff into the national database. Reuters

That puts extra pressure on next week’s report. Even if Palantir delivers a textbook beat, investors could still shrug if they think the stock leaves no margin for slip-ups. Any hint of softer guidance, sluggish deal flow, or a slowdown in U.S. commercial business would hand critics more ammunition. For the moment, Palantir’s still seen as an AI software heavyweight—with a share price that assumes the growth story isn’t letting up.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Cramer Sees Moderna's Pipeline Opening Up Beyond Covid
    July 1, 2026, 7:50 PM EDT. CNBC's Jim Cramer said on Mad Money that Moderna now looks different than during the Covid rush, with a cancer pipeline and vaccines reaching outside infectious diseases. He sees many programs still years out but calls for buying pullbacks, pointing to Moderna's track to profits and new data from late-stage cancer trials-like the melanoma combo trial with Merck's Keytruda. Moderna shares have jumped almost 150% this year but still trade under pandemic highs. Cramer also mentions fresh regulatory wins, including FDA advisory backing for its flu shot and a European nod for its combined Covid-flu vaccine.
Stock Market Today: Nasdaq Futures Sink as OpenAI Jolt and $110 Oil Threaten Record Rally
Previous Story

Stock Market Today: Nasdaq Futures Sink as OpenAI Jolt and $110 Oil Threaten Record Rally

Intel Stock Hits Record High as Google AI Chip Report Puts Foundry Turnaround in Play
Next Story

Intel Stock Hits Record High as Google AI Chip Report Puts Foundry Turnaround in Play

Go toTop